Literature DB >> 25242019

Validation of the Arabic Version of the Memorial Symptom Assessment Scale Among Lebanese Cancer Patients.

Huda Abu-Saad Huijer1, Knar Sagherian2, Hani Tamim3.   

Abstract

CONTEXT: To our knowledge, there have been no previous attempts to translate the Memorial Symptom Assessment Scale (MSAS) into the Arabic language and validate it among the Arab cancer population.
OBJECTIVES: The purpose of this study was to validate the MSAS in Arabic (MSAS-Leb) among 190 Lebanese oncology outpatients.
METHODS: The questionnaires were the MSAS-Leb and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30). Data were collected between 2009 and 2010 at a major teaching hospital in Lebanon. The psychometric indices used were reliability, convergent validity, principle component analysis, and confirmatory factor analysis (CFA).
RESULTS: The Cronbach's alpha coefficients for the MSAS and its subscales ranged from 0.71 to 0.83. On convergent validity testing, the psychological and global distress index subscales were moderately correlated (r > -0.50; P < 0.01) with the emotional functioning subscale of the EORTC QLQ-C30. Correlation coefficients between the MSAS items and selected subscales from the EORTC QLQ-C30 met the standards of convergent validity (r = -0.55 to 0.81; P < 0.01) except for the nausea/vomiting subscale. On principal component analysis (N = 95), four meaningful clusters were recovered. The clusters represented the psychological and physical components. CFA (N = 95) showed an acceptable model and a good fit (goodness-of-fit index = 0.59, adjusted goodness-of-fit index = 0.51, root mean square residual = 0.05, root mean square error of approximation = 0.2) with our data set.
CONCLUSION: The MSAS-Leb has acceptable psychometric properties of reliability and validity. We recommend its use in clinical practice and outpatient settings among health care professionals to assess and follow-up on symptom burden among patients diagnosed with cancer.
Copyright © 2015 American Academy of Hospice and Palliative Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cancer; MSAS; lebanon; psychometrics; scale; symptoms

Mesh:

Year:  2014        PMID: 25242019     DOI: 10.1016/j.jpainsymman.2014.08.014

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  6 in total

Review 1.  The psychometric properties of cancer multisymptom assessment instruments: a clinical review.

Authors:  Aynur Aktas; Declan Walsh; Jordanka Kirkova
Journal:  Support Care Cancer       Date:  2015-04-19       Impact factor: 3.603

2.  Symptom clusters in patients receiving chemotherapy: A systematic review.

Authors:  Carolyn S Harris; Kord M Kober; Yvette P Conley; Anand A Dhruva; Marilyn J Hammer; Christine A Miaskowski
Journal:  BMJ Support Palliat Care       Date:  2021-12-17       Impact factor: 3.568

3.  Symptom experience and symptom burden of patients following first-ever stroke within 1 year: a cross-sectional study.

Authors:  Dan Shi; Zheng Li; Jian Yang; Bang-Zhong Liu; Hui Xia
Journal:  Neural Regen Res       Date:  2018-11       Impact factor: 5.135

4.  The Symptom Burden and Quality of Life in Cancer Patients in the Gaza Strip, Palestine: A Cross-Sectional Study.

Authors:  Yousuf ElMokhallalati; Enas Alaloul; Mohammed Shatat; Tasneem Shneewra; Saad El Massri; Omar Shaer; Samuel Relton; Hammoda Abu-Odah; Matthew J Allsop
Journal:  PLoS One       Date:  2022-01-13       Impact factor: 3.240

5.  Symptom Prevalence in Spanish and Colombian Oncology Patients Measured with the MSAS.

Authors:  Inés Llamas-Ramos; Rocío Llamas-Ramos; Gloria Mabel Carrillo-González; Jennifer Sepúlveda-Ramírez; Elizabeth Vargas-Rosero
Journal:  Cancers (Basel)       Date:  2022-03-23       Impact factor: 6.639

6.  Assessment of Symptoms in Cancer Patients Undergoing Chemotherapy in Northern Greece.

Authors:  Maria Lavdaniti
Journal:  Mater Sociomed       Date:  2015-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.